Thursday, November 19, 2020

Phase 2 trial of Oxford COVID-19 vaccine in healthy older adults finds it is safe and provokes immune response

The UK's vaccine against SARS-CoV-2 shows similar safety and immunogenicity results in healthy older adults (aged 56 years and over) to those seen in adults aged 18-55 years. The promising early stage results are published in The Lancet.